Knowledge of chronic hepatitis C among East London primary care physicians following the Deparment of Health's educational campaign

QJM: An International Journal of Medicine

Volumn 97, Issue 6, 2004, Pages 331-336

  D'Souza, R F C ^b   Glynn, M J ^b   Alstead, E ^b   Osonayo, C ^a   Foster, G R ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Hepatobiliary Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DISEASE TRANSMISSION; FETOMATERNAL TRANSFUSION; GENERAL PRACTITIONER; GOVERNMENT; HEALTH EDUCATION; HEALTH PROMOTION; HEPATITIS C; HUMAN; INFECTION RISK; INTERVIEW; LIVER CIRRHOSIS; MEDICAL PRACTICE; PHYSICIAN; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM;

EID: 3042546952     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hch060     Document Type: Article

References (18)

1. WHO Global surveillance and control of hepatitis C. J Viral Hep 1999; 6:35-47.
2. Hepatitis C Strategy for England. [http://www.doh.gov.uk/cmo/hcvstrategy/77097dhhepcstrat.pdf]
3. Ouzan D, Cavailler P, Hofliger P, Mamino C, Joly H, Tran A. Modalities of care in anti-HCV positive patients identified in General Medicine in the Alpes-Maritimes district. Gastroenterol Clin Biol 2003; 27:376-80.
4. Ouzan D, Hofliger P, Cavailler P, Mamino C, Tran A. Screening and hepatitis C management survey in in General Medicine in the Alpes-Maritimes district and east Var area. Gastroenterol Clin Biol 2003; 27:90-3.
5. Shehab TM, Sonnod SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat 2001; 8:377-83.
6. Gupta L, Puech M, Ward J. Service expectations, self-reported educational and resource needs of general practitioners in managing patients with hepatitis C. Drug and Alcohol Review 2000; 19:65-71.
7. Zanetti A, Tanzi E, Paccagnini S, et al. Mother to infant transmission of HCV. Lancet 1995; 345:289-91.
8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
10. Tong M, El-Farrah N, Reikes A, Co R. Clinical outcomes after transfusion associated hepatitis C virus. New Engl J Med 1995; 332:1463-6.
11. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349:825-32.
12. Stein K, Rosenberg W, Wong J. Cost effectiveness of therapy for chronic hepatitis C: a decision analystic model. Gut 2002; 50:253-8.
13. Zdanuk S, Gimpel J, Uhanova J, Kaita KD, Minuk GY. The impact of medical informatics on the confidence of rural physicians caring for patients with chronic hepatitis C viral infections. Fam Pract 2001; 18:602-4.
14. Pradat P, Caillat-Vallet E, Sahajian F, Bailly G, et al. Prevalence of hepatitis C infection among general practice patients in the Lyon area, France. Eur J Epidemiol 2001; 17:47-51.
15. Fischer LR, Conboy KS, Tope DH, Shewmake DK. Educating health professionals: a hepatitis C educational program in a health maintenance organisation. Am J Manag Care 2000; 6:1029-36.
16. Dev A, Sievert W. A survey of Australian general practice management of hepatitis C infected patients from non-English speaking backgrounds. J Gastroenterol Hepatol 2002; 17:295-300.
17. Steeh C. Trends in nonresponse rates. Public Opin Quart 1998; 45:40-57.
18. Day C, Ross J, Dolan K. Hepatitis C related discrimination among heroin users in Sydney: drug user or hepatitis C discrimination? Drug and Alcohol Review 2003; 22:317-21.